Indore Plant Quarterly Output
₹36-38 crore
+44% QoQ
Output increased from ~₹25 crore in Q2 as CMO and internal production ramp.
GUFICBIOSCIENCES
Other
10 Feb 2026
Gufic Biosciences Limited — Q3 FY26
Gufic Biosciences reported Q3 FY26 revenue of ₹231.1 crore, flat sequentially, as a conscious ₹14-16 crore revenue hit from restructuring critical care and SPARSH distribution to reduce debtor days from 140 to 120 masked underlying growth.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Gufic Biosciences reported Q3 FY26 revenue of ₹231.1 crore, flat sequentially, as a conscious ₹14-16 crore revenue hit from restructuring critical care and SPARSH distribution to reduce debtor days from 140 to 120 masked underlying growth. Exports grew ~40% YoY, while domestic branded business grew only ~8% due to the working capital correction. Indore plant utilization reached ~36-38 crore quarterly output (from 20-25 crore), with EU GMP audit completed in December and certificate expected by March/April, enabling regulated market exports from Q4/Q1. Management guided 15% minimum revenue growth for FY27, with EBITDA margins expected to improve from 16% to 19% as Indore utilization exceeds 50%. Key risk: debt remains elevated at ₹375 crore, with no reduction expected before FY28.
Key Numbers
Exports Growth
~40% YoY
+40% YoY
Formulation exports grew strongly, contributing majority of incremental revenue.
Debtor Days
~120 days
-20 days YoY
Targeting reduction from 140 days in FY25 to 120 days in FY26 via distribution overhaul.
Botulinum Toxin Market Share
23%
+2-3pp YoY
Stonox holds 23% share in India's ₹20-22 million botox market, growing 20-25%.
Management Guidance
FY27 revenue growth of at least 15%
Management guided a minimum 15% topline growth for FY27, with potential upside to 20% if positive factors materialize.
Management guidance revenueEBITDA margin to improve to 19% by FY28
As Indore utilization exceeds 50%, EBITDA margin expected to rise from current 16% to 19%, and to 20-21% at >75% utilization.
Management guidance marginsIndore EU GMP certificate by March-April 2026
EU audit completed in December 2025; certificate expected by March or April, enabling regulated market exports from Q4/Q1.
Management guidance expansionFiller product launch by June-July 2026
Licensing deal with a Canadian company for dermal fillers; product launch expected in June-July to complement botox portfolio.
Management guidance growthKey Risks
Elevated debt levels constrain cash flows
Total debt stands at ₹375 crore and is expected to remain at that level through FY27, limiting ability to reduce interest burden.
high · analyst_questionWorking capital correction may persist
The restructuring of critical care and SPARSH distribution could continue to impact revenue in Q4, with an additional ₹3-5 crore hit expected.
medium · management_commentaryIndore ramp-up dependent on regulatory approvals
Export revenue from Indor hinges on timely receipt of EU GMP certificate; any delay could push back revenue contribution.
medium · management_commentaryEmployee cost base remains elevated
Employee expenses have risen to ~₹40 crore per quarter and are expected to increase 7% annually, pressuring margins until Indore scales.
medium · analyst_questionNotable Quotes
We don't want to compromise the ramp up in terms of the backing capital by just in the Indian market still give those 3Bs without any recourse.
I always feel that when we putting me on the block 15% is high time we give you bare minimum and whatever goes beyond we all should be happy.
After 2-3 years when the capacity utilization of indoor will rise more than 50%, we expect the margin again margin will be raised from 16% to 19%.
Frequently Asked Questions
What was Gufic Biosciences's revenue in Q3 FY26?
Gufic Biosciences reported revenue of ₹231 Cr in Q3 FY26, representing a — change compared to the same quarter last year.
What guidance did Gufic Biosciences management give for FY27?
FY27 revenue growth of at least 15%: Management guided a minimum 15% topline growth for FY27, with potential upside to 20% if positive factors materialize. EBITDA margin to improve to 19% by FY28: As Indore utilization exceeds 50%, EBITDA margin expected to rise from current 16% to 19%, and to 20-21% at >75% utilization. Indore EU GMP certificate by March-April 2026: EU audit completed in December 2025; certificate expected by March or April, enabling regulated market exports from Q4/Q1. Filler product launch by June-July 2026: Licensing deal with a Canadian company for dermal fillers; product launch expected in June-July to complement botox portfolio.
What are the key risks for Gufic Biosciences in FY27?
Key risks include Elevated debt levels constrain cash flows — Total debt stands at ₹375 crore and is expected to remain at that level through FY27, limiting ability to reduce interest burden.; Working capital correction may persist — The restructuring of critical care and SPARSH distribution could continue to impact revenue in Q4, with an additional ₹3-5 crore hit expected.; Indore ramp-up dependent on regulatory approvals — Export revenue from Indor hinges on timely receipt of EU GMP certificate; any delay could push back revenue contribution.; Employee cost base remains elevated — Employee expenses have risen to ~₹40 crore per quarter and are expected to increase 7% annually, pressuring margins until Indore scales..
Did Gufic Biosciences meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Gufic Biosciences Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.